ReviewTranslational gastroenterology and hepatology2025
Elimination of hepatitis C in the Middle East: a narrative review of the efficacy of direct-acting antiviral therapies.
Review in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Hepatitis C virus (HCV), is a major health concern in the Middle East. Recent advances in direct-acting antivirals (DAAs) have transformed the treatment of HCV. The DAA chosen depends on the HCV genotype (GT) responsible for the infection, presence of cirrhosis, and prior treatment attempts. In addition, factors such as human immunodeficiency virus (HIV) co-infection and renal impairment can influence treatment. This literature review aims to discuss and appraise evidence on the efficacy and safety of the DAAs currently licensed for hepatitis C treatment in the Middle East. Methods: Supporting publications from the National Institute for Health and Care Excellence (NICE) and European Association for the Study of the Liver guidelines were searched manually. A literature search of PubMed, MEDLINE, Cochrane Library, and EMBASE databases was performed with search terms including 'HCV', 'clinical trial', and the seven combinations of DAA combinations recommended by NICE. Papers from January 2016 to January 2021 were considered, along with seminal papers outside this range. Key Content and Findings: Of 390 publications found, 62 were included. In most studies, DAAs showed high efficacy in the recommended GTs, cirrhosis states, and prior HCV treatments. DAAs were found to be generally safe and well-tolerated: the most common side effects throughout were headache and nausea. Serious adverse events (SAEs) were seen when ribavirin and peginterferon alfa were taken in combination with the DAA. Conclusions: This review demonstrates the strong evidence for the efficacy and safety of DAAs. The focus of HCV research should shift from efficacy of treatment to investigating accessible screening and diagnostics in order to achieve the World Health Organisation's (WHO's) goal of eradicating HCV by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.